Spigel DR, et al. - In this phase 2 trial, patients with newly diagnosed, histologically-confirmed non-squamous non–small cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status of 2, were randomized to 1 of 3 regimens: pemetrexed; pemetrexed and bevacizumab; or pemetrexed, carboplatin, and bevacizumab. It was found that all 3 regimens were feasible for patients with advanced NSCLC and an ECOG performance status of 2. An increase in the overall response rate was noted as a result of adding bevacizumab to pemetrexed. The efficacy of pemetrexed/carboplatin/bevacizumab (median progression-free survival, 4.8 months) approached the prespecified study progression-free survival goal of 5 months.